Randomized Mechlorethamine/Chlormethine Induced Dermatitis Assessment Study (MIDAS) Establishes Benefit of Topical Triamcinolone 0.1% Ointment Cotreatment in Mycosis Fungoides
Carolina V Alexander-Savino, Catherine G Chung, Elaine S Gilmore, Sean M Carroll, Brian Poligone, Carolina V Alexander-Savino, Catherine G Chung, Elaine S Gilmore, Sean M Carroll, Brian Poligone
Abstract
Introduction: Treatment of early-stage mycosis fungoides (MF) requires safe, skin-directed therapies. Medication side effects can lead to underutilization of effective therapies. The objective of this study was to assess the use of topical triamcinolone 0.1% ointment as a means of reducing contact dermatitis associated with topical mechlorethamine/chlormethine gel for the treatment of MF.
Methods: This prospective, randomized, open-label study evaluated 28 adults with mycosis fungoides who were eligible for treatment with topical mechlorethamine/chlormethine gel from December 17, 2017 to December 23, 2020. Patients were treated for 4 months with clinical follow-up through 12 months. Patients had half of their lesions also treated with topical triamcinolone 0.1% ointment (while the other half were treated with mechlorethamine/chlormethine alone). The study was self-controlled with separate lesions in the same patient receiving each treatment arm. Treatment arms were determined by the flip of a coin.
Results: Twenty-eight patients enrolled (17 men (61%) and 11 women (39%)). Demographics included 25 White, 2 African Americans, and 1 Asian patient. Twenty-five completed the 12-month follow-up. Triamcinolone 0.1% ointment led to increased tolerability of mechlorethamine/chlormethine gel but did not change the efficacy of mechlorethamine/chlormethine. There was a statistically significant 50% decrease in dermatitis (SCORD score) at month 2 in the triamcinolone-treated arm.
Conclusions: Topical triamcinolone ointment is a helpful adjuvant therapy when treating patients with topical mechlorethamine/chlormethine gel. It diminishes inflammation and does not reduce efficacy. The peak incidence of dermatitis in the study occurred in the second and third months.
Trial registration: ClinicalTrials.gov identifier, NCT03380026.
Keywords: Contact dermatitis; Drug reactions; Lymphoma; MF; Patch testing; Prescription drug management; Therapeutics.
© 2022. The Author(s).
Figures
References
- Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. J Am Acad Dermatol. 2005;53(6):1053–63. doi: 10.1016/j.jaad.2005.08.057.
- Mehta-Shah N, Horwitz SM, Ansell S, et al. NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 1.2021. J Natl Compr Cancer Netw. 2021.
- Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome; Update 2017. Eur J Cancer [Internet]. 2017;77:57–74. doi: 10.1016/j.ejca.2017.02.027.
- Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol [Internet]. 2018;29:iv30–40. doi: 10.1093/annonc/mdy133.
- Querfeld C, Pacheco T, Haverkos B, et al. A Little Experience Goes a Long Way: Chlormethine/Mechlorethamine Treatment Duration as a Function of Clinician-level Patient Volume for Mycosis Fungoides Cutaneous T-cell Lymphoma (MF-CTCL) - a Retrospective Cohort Study. Front Med [Internet]. 2021;8:921.
- Lessin SR, Duvic M, Guitart J, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol [Internet]. 2013;149(1):25–32. doi: 10.1001/2013.jamadermatol.541.
- Krumbhaar EB. Role of the blood and the bone marrow in certain forms of gas poisoning. J Am Med Assoc. 1919.
- Haserick JR, Richardson JH, Grant DJ. Remission of lesions in mycosis fungoides following topical application of nitrogen mustard: a case report. Cleve Clin J Med. 1959.
- Van Scott EJ, Winters PL. Responses of mycosis fungoides to intensive external treatment with nitrogen mustard. Arch Dermatol. 1970.
- Kim YH, Martinez G, Varghese A, Hoppe RT. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol. 2003;139(2):165–73.
- Price NM, Constantine VS, Hoppe RT, Fuks ZY, Farber EM. Topical mechlorethamine therapy for mycosis fungoides. Br J Dermatol. 1977;97(5):547–50. doi: 10.1111/j.1365-2133.1977.tb14133.x.
- Price NM, Hoppe RT, Deneau DG. Ointment‐based mechlorethamine treatment for mycosis fungoides. Cancer. 1983.
- Ramsay DL, Parnes RE, Dubin N. Response of mycosis fungoides to topical chemotherapy with mechlorethamine. JAMA Dermatology [Internet]. 1984;120(12):1585–90. doi: 10.1001/archderm.1984.01650480047016.
- Esteve E, Bagot M, Joly P, et al. A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas. French Study Group of Cutaneous Lymphomas. Arch Dermatol [Internet]. 1999;135(11):1349–53.
- De Quatrebarbes J, Estève E, Bagot M, et al. Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study. Arch Dermatol. 2005.
- Van Scott EJ. Complete regressions of mycosis fungoides with topical mechlorethamine hydrochloride. JAMA [Internet]. 1972;222(9):1172. doi: 10.1001/jama.1972.03210090052026.
- Ramsay DL, Halperin PS, Zeleniuch-Jacquotte A. Topical mechlorethamine therapy for early stage mycosis fungoides. J Am Acad Dermatol. 1988;19(4):684–91. doi: 10.1016/S0190-9622(88)70223-6.
- Kunz B, Oranje AP, Labrèze L, Stalder JF, Ring J, Taïeb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195(1):10–9. doi: 10.1159/000245677.
- Kartan S, Shalabi D, O’Donnell M, et al. Response to topical corticosteroid monotherapy in mycosis fungoides. J Am Acad Dermatol [Internet]. 2021;84(3):615–23. doi: 10.1016/j.jaad.2020.05.043.
- Vonderheid EC, Ekbote SK, Kerrigan K, et al. The prognostic significance of delayed hypersensitivity to dinitrochlorobenzene and mechlorethamine hydrochloride in cutaneous T cell lymphoma. J Invest Dermatol. 1998;110(6):946–50. doi: 10.1046/j.1523-1747.1998.00206.x.
- Rasmussen JE. Percutaneous absorption of topically applied triamcinolone in children. Arch Dermatol [Internet]. 1978;114(8):1165–7. doi: 10.1001/archderm.1978.01640200019005.
Source: PubMed